HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) with a maintained price target of $9.
May 09, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Aquestive Therapeutics with a $9 price target.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on AQST's stock price. The analyst's bullish stance suggests a strong belief in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100